Abivax SA
PAR:ABVX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Yixin Group Ltd
HKEX:2858
|
CN |
|
Asian Paints Ltd
NSE:ASIANPAINT
|
IN |
Abivax SA
Accounts Payable
Abivax SA
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Abivax SA
PAR:ABVX
|
Accounts Payable
€43.8m
|
CAGR 3-Years
41%
|
CAGR 5-Years
20%
|
CAGR 10-Years
32%
|
|
|
Valneva SE
PAR:VLA
|
Accounts Payable
€9.1m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-2%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Accounts Payable
€26.4m
|
CAGR 3-Years
45%
|
CAGR 5-Years
5%
|
CAGR 10-Years
17%
|
|
|
Inventiva SA
PAR:IVA
|
Accounts Payable
€34.7m
|
CAGR 3-Years
21%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Accounts Payable
$17.3m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
9%
|
|
|
DBV Technologies SA
PAR:DBV
|
Accounts Payable
$40.9m
|
CAGR 3-Years
41%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
Abivax SA
Glance View
Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.
See Also
What is Abivax SA's Accounts Payable?
Accounts Payable
43.8m
EUR
Based on the financial report for Dec 31, 2025, Abivax SA's Accounts Payable amounts to 43.8m EUR.
What is Abivax SA's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
32%
Over the last year, the Accounts Payable growth was 0%. The average annual Accounts Payable growth rates for Abivax SA have been 41% over the past three years , 20% over the past five years , and 32% over the past ten years .
